Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study

OBJECTIVE: The use of adjuvant endocrine therapy (AET) after primary treatment of hormone receptor‐positive breast cancer reduces the risk of recurrence and mortality. However, non‐adherence is still common. Limited consideration has been given to how users deal with AET and the role of pharmaceutic...

Descripción completa

Detalles Bibliográficos
Autores principales: En‐nasery ‐ de Heer, Selma, Tromp, Vashti N. M. F., Westerman, Marjan J., Konings, Inge, Beckeringh, Jan Jacob, Boons, Christel L. M., Timmers, Lonneke, Hugtenburg, Jacqueline G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786726/
https://www.ncbi.nlm.nih.gov/pubmed/36300863
http://dx.doi.org/10.1111/ecc.13749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786726/
https://www.ncbi.nlm.nih.gov/pubmed/36300863
http://dx.doi.org/10.1111/ecc.13749

Ejemplares similares